14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today DVAX ranks #14734 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Dynavax Technologies Corporation Stock Forecast NASDAQ:DVAX

$12.73 (0%)

Volume: 2M

Closed: Jan 19, 2022

Hollow Logo Score: -3.574

Dynavax Technologies Corporation Stock Forecast

$12.73 (0%)

Volume: 2M

Closed: Jan 19, 2022

Score Hollow Logo -3.574

Dynavax Technologies Corporation Company Profile

2929 Seventh Street

Berkeley CA 94710



Dynavax Technologies Corporation


Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial. Its product portfolio also comprises AZD1419 for the treatment of asthma, which is in Phase II clinical trial; DV1179, a TLR7/9 inhibitor that is in Phase Ib/IIa for the treatment of autoimmune and inflammatory conditions; and DV281 and CpG-Nanoparticles, which are in preclinical studies for cancer immunotherapy. It has a research collaboration and license agreement with AstraZeneca AB to conduct a Phase IIa safety and efficacy trial of AZD1419 for the treatment of asthma; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE